Blog
Rayner my parade! The importance of specialist advice.
Jemma Brimblecombe
As the recent Anti-Corruption Summit in London drew to a close the outcome was clear – the focus is firmly on holding companies to account and UK corporates are well and truly in the firing line.
The Competition and Markets Authority (‘CMA’) has warned that UK companies and in particular large pharmaceutical companies are to expect “substantial fines”. Alex Chisholm, Chief Executive of the CMA wants to see “a big step up in the scale and impact of [their] enforcement activity”. Whilst he acknowledges that this is not the goal by which the CMA’s success should be measured, it is, however one element which acts as a credible deterrent. He goes on to say that in high value markets involving big players, such players should be ready to face big fines.
In a report published on 5 February, the National Audit Office (NAO) congratulated the Competition and Markets Authority (CMA) for “significant progress” in improving how the UK’s competition regime works confirming that, it is now “more coherent than ever”. However, it called for further action to step up the flow of successful enforcement cases and the need for greater awareness amongst business of competition law. Flexibility of resourcing and greater co-operation to secure a coherent approach across the regime is called for.
Jemma Brimblecombe
Charles Richardson
Oliver Oldman
Skip to content Home About Us Insights Services Contact Accessibility